TRIMER Biotech, LLC Acquires Humanized Anti-TNF-α Antibody from Lilly

TRIMER Biotech, LLC is pleased to announce the successful acquisition of AME-527, an anti-TNF-α monoclonal antibody under development by Eli Lilly and Company for autoimmune disorders.
By: Trimer Biotech, LLC
 
June 1, 2012 - PRLog -- DALLAS, TX – June 1, 2012 – TRIMER Biotech, LLC is pleased to announce the successful acquisition of AME-527, an anti-TNF-α monoclonal antibody under development by Eli Lilly and Company for autoimmune disorders. AME-527 is a subcutaneously administered, fully humanized, high-affinity monoclonal antibody for which Phase I/II clinical development has been completed in patients with rheumatoid arthritis (RA) who failed at least 1 DMARD (disease modifying antirheumatic drugs).

The TNF-α is a validated target for the treatment of patients with autoimmune disorders like rheumatoid arthritis (RA). AME-527 is a fully humanized antibody and has been optimized through protein engineering for increased affinity for TNF-α.

In phase I/II clinical trial of AME-527, eighteen patients with recurrent rheumatoid arthritis (RA) who failed at least 1 DMARD were treated. The results showed that AME-527 is well tolerated at all four (1, 3, 10, or 30 mg), six-weekly doses cohorts. Based on PK, PD, and efficacy measured by ACR response criteria, 10mg/week was selected as optimal therapy. Patients responding to AME-527 (ACR-20 or greater) were allowed to continue assigned dose or optimal dose (whichever was lower) for up to 1 year (Extended Treatment).

“We are very excited about this acquisition.  The clinical results to date suggest that AME-527 has the potential to improve therapeutic options for patients with autoimmune disorders” says Dr. Vinay Jain, CEO of TRIMER Biotech.  

TRIMER acquired full rights to develop AME-527 for all human therapeutic, prophylactic, and diagnostic uses.  The company intends to continue the development of AME-527 for the treatment of RA and other autoimmune disorders including inflammatory bowel disease.

About TRIMER Biotech, LLC:
TRIMER Biotech is a privately held limited liability company (LLC) based in Dallas, TX. TRIMER is committed to the development of more effective and convenient anti-TNF-α antibodies for autoimmune disorders in order to increase the number of treatment options and make treatments available to a broader segment of the population. For more information about TRIMER Biotech, please visit us at www.trimerbio.com or contact us by email at info@trimerbio.com or by phone at 214 593.5000.
End
Source:Trimer Biotech, LLC
Email:***@trimerbio.com Email Verified
Tags:AME-527, Rheumatoid Arthritis, anti-TNF-alpha antibody, Monoclonal Antibody, Humanized
Industry:Clinical Development
Location:United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share